1 / 52

Number Needed to Treat

Number Needed to Treat. Alex Djuricich, MD Indiana University School of Medicine Department of Medicine Ambulatory Rotation 2006-2007. Objectives. To learn basic information used in evaluating articles about therapy

colm
Download Presentation

Number Needed to Treat

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Number Needed to Treat Alex Djuricich, MD Indiana University School of Medicine Department of Medicine Ambulatory Rotation 2006-2007

  2. Objectives • To learn basic information used in evaluating articles about therapy • To learn definitions of the following and be able to apply them to appraising articles on therapy: • CER (Control event rate) • EER (Experimental event rate) • RRR (Relative risk reduction) • ARR (Absolute risk reduction) • NNT (Number Needed to Treat)

  3. Objectives • To learn the “correlaries” to each of these definitions for harm • RRI (Relative risk increase) • ARI (Absolute risk increase) • NNH (Number needed to harm)

  4. Hypothetical trial • Trial of 1000 patients to compare use of MiGone (I made that one up? Like the name? Get it?) vs. placebo to prevent MI, given over 5 years. Patients for study are all healthy gym rats, coming from Bally’s Gym.

  5. Trial stats

  6. For MI • CER • 20/400 = 0.05, or 5% • EER • 18/600 = 0.03, or 3% • ARR • 0.05 – 0.03 = 0.02, or 2% • RRR • (0.05 – 0.03)/0.05 = 0.02/0.05 = 40%

  7. For MI • NNT • 1/ARR • 1/0.02 = 50 • 50 patients would need to be treated to prevent one MI in 5 years in Bally’s Gym patients

  8. For myalgias • CER • 4/400 = 0.01, or 1% • EER • 12/600 = 0.02, or 2% • ARI • 0.02 – 0.01 = 0.01, or 1% • RRI • 0.02 – 0.01/0.01 = 0.01/0.01 = 1, or 100%

  9. For myalgias • NNH • 1/ARI • 1/0.01 = 100 • 100 patients would need to be treated with MiGone over 5 years to cause one case (harm) of myalgias

  10. Case #1 • You just completed your GI rotation, and are now doing Wishard wards. • You admit a 50 year old alcoholic gentleman for abdominal pain. After imaging, you find that he has radiologic “cirrhosis” with evidence of portal hypertension. He has NEVER had an upper GI bleed

  11. Case #1 continued • You discuss preventive pharmacologic treatments in rounds with the attending • In patient with cirrhosis and portal hypertension, does a non-selective beta blocker prevent gastroesophageal varices? • Yes • No

  12. Article • Beta-blockers to prevent gastroeophageal varices in patients with cirrhosis • Groszmann RJ, et al. New Engl J Med 2005;353:2254-61.

  13. Focus on Table #2

  14. Control Event Rate • Percentage of those controls who develop the unwanted condition • In our example, varices or complication from it • 42/105 • 40%

  15. Experimental Event Rate • Percent of those in treatment group that developed the condition (varices) • 42/108 • 38.9%

  16. Absolute Risk Reduction • The true reduction in risk between control patients and treated patients • Difference between the CER and the EER • CER – EER • 0.4 – 0.389 • 0.011, or 1.1% • That’s ok, but not very impressive!

  17. Relative Risk Reduction • (CER – EER)/CER • (0.4 – 0.389)/0.4 • 0.011/0.4 • 0.0275, or 2.75% • Remember, 2.75% sounds better than 1.1%, but it still isn’t very “good”

  18. Number Needed to Treat (NNT) • Meaningful way of expressing benefit of an active treatment over a control • Defines treatment-specific event of an intervention

  19. NNT • Expression of the # of patients one would need to treat to prevent 1 additional adverse outcome (MI) or attain one additional benefit • 1/ARR • 1/0.011 • 91 (that is, 91 patients would need to be treated with timolol to prevent one additional case of varices) • Impressive? Not impressive?

  20. NNT • Function of 4 elements • Condition Cirrhosis pts • Intervention Timolol vs. placebo • Events being prevented Varices • Duration of follow-up 55 months • Remember “DICE”

  21. NNT • Tells us in more concrete terms how much effort clinicians must expend to prevent one event, thus allowing comparisons with the amounts of efforts that must be expended to prevent the same or other events in patients with disorders

  22. NNT • Is a “good” NNT a low or a high number? • The lower the NNT, the larger the magnitude of treatment effect

  23. What about the “serious adverse events”? • Need to remember that medications have side effects, and that one can calculate how often we “harm” someone by giving a medication designed to help. • This “harm” is the side effect

  24. CER • For harm, the CER is still the same as before. • However, it applies to the harm instead of the “good” effect • In the example, it refers to “serious adverse events” (such as bradycardia)

  25. EER • This is really the same as before, except it applies to the rate for harm instead of for benefit • In our example, the EER is for “serious adverse events”

  26. ARI for “Harm” • Absolute Risk Increase • EER – CER • Note NOT “CER – EER”

  27. RRI • Relative Risk Increase • (EER – CER)/CER • Remember, its always the Control that goes in the denominator

  28. What about NNH? • In general, a decision to use therapy involves risk vs. benefit • Most therapies have side effects • Same concepts for NNT apply to side effects. We call that number the NNH (number needed to harm)

  29. NNH • The number of patients who, if they received the experimental treatment, would lead to one additional patient being “harmed”, compared with patients who received the comparison treatment. • 1/ARI

  30. Table #2 Again

  31. Let’s calculate for “serious adverse events” • CER • 6/105 (5.7%) • EER • 20/108 (18.5%)

  32. For “adverse events” • ARI • 18.5% - 5.7% = 12.8%, or 0.128 • RRI • (18.5% - 5.7%) / 5.7%= 224.5%, or 2.245 • NNH • 1/ARI • 1/0.128 • 7.8 (rounds to 8) patients need to be treated with timolol to cause one case of “serious adverse events” • This is unfortunately not a very good number; we want a very high NNH (as opposed to NNT)

  33. Case Take Home • According to this one study, the numbers are not impressive enough to recommend timolol to PREVENT varices in patients with diagnosed cirrhosis. • Remember that this is different from patients who have ALREADY had an upper GI bleed from varices secondary to cirrhosis. Those patients should get a beta blocker.

  34. Questions?

  35. Case #2 • You admit a patient on University Wards at night for bacterial meningitis. The ER doctor calls you with results of the CSF showing a WBC count of 1024, after noting cloudy CSF from the tap. She wants to know which antibiotic you would like to use; need an answer in 1 minute; meningitis is a true medical emergency!! • You recall from your pediatrics rotation about giving steroids in addition to antibiotics. • In patients with bacterial meningitis, does the use of concomitant dexamethasone improve neurological outcome?

  36. Example NEJM paper • Dexamethasone in adults with bacterial meningitis • deGans J, vandeBeek D, et al. New Engl J Med 2002;347:1549-56. • Total patients: 301 patients • 157 in dexamethasone (experimental) group • 144 in placebo (control) group

  37. NNT: Function of 4 elements • 1. Condition • meningitis • 2. Intervention • dexamethasone vs. placebo. Keep in mind that other treatments (antibiotics) were given to both groups, so placebo isn’t really “nothing” • 3. Events being prevented • unfavorable outcome (they define it), death • 4. Duration of follow-up • 8 weeks

  38. Dexamethasone paper

  39. Dexamethasone paper • CER for unfavorable outcome • 36/144 • 0.25, or 25% • CER for death • 21/144 • 0.25, or 15%

  40. Dexamethasone paper • EER for unfavorable outcome • 23/157 • 0.15, or 15% • EER for death • 11/157 • 0.07, or 7%

  41. Dexamethasone paper • ARR for unfavorable outcome • CER – EER • 0.25 – 0.15 • 0.10, or 10% • ARR for death • CER – EER • 0.15 – 0.07 • 0.08, or 8%

  42. Dexamethasone paper • NNT for unfavorable outcome • 1/ARR • 1/0.10 • 10. You would need to treat 10 meningitis patients with dexamethasone to prevent one patient getting an “unfavorable outcome” after 8 weeks • NNT for death • 1/ARR • 1/0.08 • 12.5 (rounds up to 13). You would need to treat 13 meningitis patients with dexamethasone to prevent one death after 8 weeks

  43. Dexamethasone • How about NNH? • Calculate it for each of the “side effects” you are interested in.

  44. Dexamethasone paper

  45. Dexamethasone paper • CER for hyperglycemia • 37/144 • 0.26, or 26% • CER for fungal infection • 4/144 • 0.03, or 3%

  46. Dexamethasone paper • EER for hyperglycemia • 50/157 • 0.32, or 32% • EER for fungal infection • 8/157 • 0.05, or 5%

  47. Dexamethasone paper • ARI for hyperglycemia • EER – CER • 0.32 – 0.26 • 0.06, or 6% • ARI for fungal infection • EER – CER • 0.05 – 0.03 • 0.02, or 2%

  48. Dexamethasone paper • NNH for hyperglycemia • 1/ARI for hyperglycemia • 1/0.06 • 16.7 (rounds to 17) • You would need to treat 17 patients with bacterial meningitis to cause one case of hyperglycemia over 8 weeks

  49. Dexamethasone paper • NNH for fungal infection • 1/ARI for fungal infection • 1/0.02 • 50 • You would need to treat 50 patients with meningitis with dexamethasone to cause one case of fungal infection over 8 weeks

  50. Case Take Home • Consider steroids at the time of diagnosis of suspected meningitis. • They clearly have a role in improving outcomes, but this comes at a cost of increased fungal infection • Is it worth the risk? That is the “art” of medicine.

More Related